FDA Clears Surrozen's SZN-8141 IND, Unlocking $95.1M Financing Milestone
SRZN has more than doubled off its 52-week low of $11.39.
Summary
Surrozen announced FDA clearance of its IND for SZN-8141, a dual-mechanism therapy for diabetic macular edema, triggering a $95.1 million second closing under its March 2025 private placement expected around October 20, 2026.
Key Events · Product Development and Regulatory · SRZN
-
FDA Clears SZN-8141 IND
The FDA cleared Surrozen's Investigational New Drug application for SZN-8141, a bifunctional Wnt agonist and VEGF antagonist for diabetic macular edema, after the 30-day review period.
-
$95.1M Second Closing Triggered
FDA clearance satisfies the second closing milestone under the March 2025 two-tranche private placement, unlocking approximately $95.1 million in gross proceeds expected on or about October 20, 2026.
-
Phase 1b/2a DUET Study Timeline
First patient dosing in the DUET study is expected in Q4 2026, with initial data expected in the second half of 2027.
-
Resale Registration to Follow
Surrozen expects to file a new S-3 registration statement within 30 days after closing to register resale of shares and warrants issued in the second closing.
Analysis · SRZN · Life Sciences
FDA clearance of the SZN-8141 IND moves Surrozen's lead ophthalmology program into clinical development and, critically, satisfies the second closing milestone under the March 2025 private placement. That unlocks approximately $95.1 million in gross proceeds expected on or about October 20, 2026 — capital that materially extends the company's runway given its going-concern warning and $127.5 million Q1 net loss. The first patient is expected to be dosed in Q4 2026, with initial data in H2 2027.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 36.3% of the 1065 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SRZN was trading at $30.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $352.6M. The 52-week trading range was $11.39 to $37.83. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.